Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance study of duvakitug in moderate to severe Crohn's disease
MOH_2026-03-23_015728Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duvakitug in Crohn's disease (9 arms), sponsored by Sanofi. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
duvakitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2026-03-23_015728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-23_015728.